Morepen Laboratories Limited (MOREPENLAB) announced the launch of its first prescription (Rx) generic product, Desloratadine Tablets USP, 5 mg, in 100-count and 500-count packs for distribution in the U.S. market. This initiative is being undertaken through its wholly owned U.S. arm, Morepen Bio Inc. Building on its established API position, this move extends the company’s participation further along the pharmaceutical value chain into finished-dosage medicines and U.S. distribution.

Strategic Expansion into Prescription Market

Sanjay Suri, Managing Director of Morepen Laboratories Limited, said, “Our long-standing API relationships in regulated markets provide a strong foundation for Morepen’s next phase of growth. Alongside our expanding CDMO business, we are selectively extending our capabilities into finished-dosage development and U.S. distribution. This reflects our strategy to build a more integrated, R&D-led pharmaceutical business with sustainable, long-term growth opportunities.”

Regulatory Milestones

The prescription generics expansion follows Morepen’s earlier U.S. OTC product introductions. Separately, the company has submitted its first Abbreviated New Drug Application (ANDA) to the U.S. FDA for Sitagliptin Phosphate Tablets USP, 25 mg, 50 mg, and 100 mg. This milestone demonstrates Morepen’s growing capabilities in formulation development, analytical science, and regulatory filings. The application is currently under regulatory review.

Looking ahead, Morepen intends to pursue additional U.S. prescription generic filings and distribution opportunities where its established API and pharmaceutical R&D capabilities provide a competitive advantage. The company may also evaluate selected opportunities in high-potency APIs (HPAPIs) and oncology, subject to development feasibility, regulatory requirements, and market conditions.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Morepen Laboratories Limited

Morepen Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Morepen gains 110.3% over three months and trades near its 52-week highs. Thin margins at 7.2% leave limited room for error — any demand softness or cost spike hits the bottom line hard. The PEG of 1.39 sits close to fair value. The stock is neither a clear buy nor obviously expensive. Buyers show up with 1.7x the volume of sellers. Moreover, they dominated on 16 of recent sessions versus 14 for sellers — a healthy accumulation pattern. The stock rises 110.3% in three months on 8.4% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Morepen Laboratories Limited.

Cohance Lifesciences Limited (COHANCE) showcased a clear sequential recovery in its Q2 FY27 investor presentation, with revenue up 13% QoQ and adjusted EBITDA margin improving to 10% from 2% in Q1. The integrated capabilities of One Cohance are strengthening the growth platform.

Strategic Progress

The integration of One Cohance is driving operational and commercial progress across businesses. In the Pharma CDMO segment, the order and reload position for Q3 and Q4 has improved materially. Cohance secured two new commercial and one late-stage programme with large global pharma customers, strengthening relationships and medium-term growth opportunities. In the nucleic acid business, Sapala’s strong performance is supported by increasing integration of its specialised chemistry and customer relationships with Cohance’s development and manufacturing network.

Financial Performance

API+ revenue grew year-on-year, supported by selective pricing actions, while lower API volumes, shipment phasing, and higher raw-material costs impacted margins. Specialty Chemicals declined YoY due to lower AgChem volumes, pricing pressure, and programme phasing, while Performance Materials remained relatively stable. The company plans to announce investments in capex towards building capabilities in adjacencies and R&D to unlock the full potential of the One Cohance platform.

Looking Ahead

H2 FY27 revenue and EBITDA are expected to grow year-on-year, supported by continued recovery and progressive integration of Cohance’s capabilities to unlock platform potential. The H2 focus is on improving revenue mix and utilisation to support progressive margin recovery.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Cohance Lifesciences Limited

Cohance Lifesciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Cohance moves sideways over three months, with neither buyers nor sellers taking control. Thin margins at 5.0% leave limited room for error — any demand softness or cost spike hits the bottom line hard. 1 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. The stock holds at 30% of its 52-week range with RSI at 58. In other words, neither side has a clear edge right now. The stock rises 5.0% in three months on 18.3% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Cohance Lifesciences Limited.

Fermenta Biotech Limited (FERMENTA) announced its financial results for Q2 FY27, showing a robust performance in the quarter. The company reported a revenue of INR 135.8 crore, up 8% from the previous quarter, and EBITDA increased by 3% QoQ to INR 23.2 crore.

Financial Highlights

The consolidated revenue for Q2 FY27 stood at INR 135.8 crore, a marginal increase of 0.1% year-on-year but an 8% rise quarter-over-quarter. The EBITDA for the quarter was INR 23.2 crore, showing a 3% QoQ growth. Profit after tax (PAT) for the quarter was INR 9.4 crore, down 48% YoY but down 1% QoQ.

Sector Performance

Human Nutrition, the primary revenue source, grew by 2% in H1 FY27 to INR 162.5 crore, contributing significantly to the overall revenue. India’s contribution to the half-year revenue rose to 51%, up from 40% a year earlier, reflecting the company’s expanding market presence.

Operational Milestones

Fermenta Biotech Limited achieved several milestones during the quarter, including the FSSAI approval for VITADEE Green® in July, the NSE listing in August, and securing an exclusive license for VIT Vellore Vitamin B12 in September. Looking ahead, the company expects to ramp up VITADEE Green® capacity from Q2 FY28 and aims to complete regulatory approvals for Calcifediol by the end of FY27.

Despite the challenges in the animal nutrition segment, Fermenta Biotech Limited continues to leverage its strengths in human nutrition and diversified markets to drive growth and maintain a low customer concentration, with the largest customer accounting for only 9% of revenue.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Fermenta Biotech Limited

Fermenta Biotech Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Fermenta rises 12.3% over three months, with buying pressure holding steady. Revenue grows at 14.5% CAGR. The company generates cash but does not compound aggressively. The stock holds at 38% of its 52-week range with RSI at 43. In other words, neither side has a clear edge right now. Revenue grows at 14.5% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Fermenta Biotech Limited.